FindTrial
Sign In

Eculizumab Injection

DRUG5 trials

Sponsors

Marmara University, Chengdu Suncadia Medicine Co., Ltd., Haisco Pharmaceutical Group Co., Ltd., Wuhan Createrna Science and Technology Co., Ltd, Nanjing Chia-tai Tianqing Pharmaceutical

Conditions

CD55 - Cluster of Differentiation Antigen 55 DeficiencyComplement Regulatory Factor DefectPNHParoxysmal Nocturnal Haemoglobinuria (PNH)Paroxysmal Nocturnal HemoglobinuriaPrimary Intestinal LymphangiectasisProtein-Losing Enteropathies

Phase 3

A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
CompletedNCT06593938
Chengdu Suncadia Medicine Co., Ltd.Paroxysmal Nocturnal Hemoglobinuria
Start: 2024-10-25End: 2025-07-31Updated: 2025-09-11
A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy
CompletedNCT06799546
Haisco Pharmaceutical Group Co., Ltd.PNH
Start: 2025-02-13End: 2025-11-05Updated: 2025-12-22
Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
RecruitingNCT06932744
Wuhan Createrna Science and Technology Co., LtdParoxysmal Nocturnal Haemoglobinuria (PNH)
Start: 2024-08-30End: 2025-12-30Target: 66Updated: 2025-05-09
A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients
Not yet recruitingNCT07177859
Nanjing Chia-tai Tianqing PharmaceuticalParoxysmal Nocturnal Hemoglobinuria
Start: 2025-11-30End: 2026-11-30Target: 78Updated: 2025-09-17

Unknown Phase

Transcriptome and Metabolic Analyses of CHAPLE Disease
NCT03950804
Marmara UniversityCD55 - Cluster of Differentiation Antigen 55 Deficiency, Complement Regulatory Factor Defect, Primary Intestinal Lymphangiectasis +1
Start: 2018-06-15End: 2020-06-15Target: 60Updated: 2019-08-14